Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
Authors Loh TY, Hsiao JL, Shi VY
Received 1 December 2019
Accepted for publication 29 January 2020
Published 11 February 2020 Volume 2020:13 Pages 109—114
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Amrita Dosanjh
Tiffany Y Loh,1 Jennifer L Hsiao,2 Vivian Y Shi1
1University of Arizona, Division of Dermatology, Tucson, AZ, USA; 2University of California Los Angeles, Division of Dermatology, Los Angeles, CA, USA
Correspondence: Vivian Y Shi
Division of Dermatology, University of Arizona, 7165 N Pima Canyon Drive, Tucson, AZ 85718, USA
Tel +1 520 694 2055
Fax +1 520 694 2005
Background: Atopic dermatitis (AD) is a chronic, relapsing skin condition with a wide disease spectrum. Moderate-to-severe cases often need systemic treatment. Conventional immunosuppressants have extensive side effect profiles and require close monitoring. In recent decades, there has been increasing interest in developing targeted systemic immunomodulators for AD, as they have been shown to have efficacy for AD as well as favorable safety profiles. Herein, we review the recent data on lebrikizumab, an interleukin (IL)-13 inhibitor, and its potential role in the treatment of AD.
Objective: Review the mechanism of action, and available data on the efficacy and safety of lebrikizumab for the treatment of AD.
Methods: PubMed, Google Scholar, and clinicaltrials.gov searches were performed with the following terms: “atopic dermatitis,” “dermatitis,” “eczema,” “lebrikizumab,” “IL-4,” and “IL-13.”
Results: Two Phase II randomized controlled clinical trials have been conducted to evaluate the use of lebrikizumab in a total of 289 patients with moderate-severe AD and inadequate response to topical corticosteroids. Patients treated with lebrikizumab experienced significantly more improvement in their AD compared to placebo, as measured by Eczema Area and Severity Index (EASI)-50 and EASI-75 scores, pruritus scores, and reduction in body surface area (BSA). Its clinical efficacy appears to be dose-dependent, and it has a favorable side effect profile and is generally well tolerated.
Conclusion: Lebrikizumab appears to be a promising emerging targeted biologic for the treatment of moderate-to-severe AD. Further Phase III studies investigating optimal dosing regimens and safety profile are needed.
Keywords: lebrikizumab, atopic dermatitis, eczema, dermatitis, IL-4, IL-13
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]